BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND ZRSR2, URP, 8233, ENSG00000169249, U2AF1RS2, MGC142040, U2AF1L2, U2AF1-RS2, MGC142014 AND Treatment
14 results:

  • 1. [RNA splicing dysregulation in hematological malignancies].
    Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
    Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center.
    Lian Y; Ti J; Ma L; Wei J; Gao Z
    Hematology; 2023 Dec; 28(1):2230738. PubMed ID: 37427790
    [No Abstract]    [Full Text] [Related]  

  • 3. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia.
    Jia W; Guo X; Wei Y; Liu J; Can C; Wang R; Yang X; Ji C; Ma D
    Mol Biol Rep; 2023 Aug; 50(8):6601-6610. PubMed ID: 37344641
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Effect of Signal Transduction Pathway Gene Mutations on the One- course Induced Remission Rate and Analysis of Clinical Characteristics in Patients with CBF-AML].
    Fan LF; Xu J; Chen XH; Tian TT; Xie J; Hu JJ; Guo ZP; Tan YH; Xu ZF; Ren FG; Zhang YF; Luo M; Ren WX; Wang HW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):781-788. PubMed ID: 32552936
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Additional gene mutations may refine the 2017 European leukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
    Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
    Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).
    Berman E; Jhanwar S; Hedvat C; Arcila ME; Wahab OA; Levine R; Maloy M; Ma W; Albitar M
    Leuk Res; 2016 Oct; 49():108-12. PubMed ID: 27658269
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Mutational spectrum of adult T-ALL.
    Neumann M; Vosberg S; Schlee C; Heesch S; Schwartz S; Gökbuget N; Hoelzer D; Graf A; Krebs S; Bartram I; Blum H; Brüggemann M; Hecht J; Bohlander SK; Greif PA; Baldus CD
    Oncotarget; 2015 Feb; 6(5):2754-66. PubMed ID: 25595890
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
    Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
    Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and zrsr2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.